{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-005424","form_type":"8-K","ticker":"AVIR","cik":"0001593899","company_name":"Atea Pharmaceuticals, Inc.","filed_at":"2025-01-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.109683+00:00","generated_at":"2026-05-28T02:03:50.105210+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Atea reports $454.7M cash, plans global Phase 3 HCV program starting Q1 2025","bullets":["Cash, cash equivalents and marketable securities $454.7M at Dec 31, 2024; cash runway into 2028.","Phase 2 study met primary endpoints: 98% SVR12 in per-protocol population, 95% in efficacy evaluable (n=256).","Global Phase 3 program for bemnifosbuvir + ruzasvir expected to initiate in Q1 2025; two open-label trials.","End-of-Phase 2 meeting with FDA scheduled January 2025 to discuss Phase 3 program design.","Company estimates global HCV market ~$3B annual net sales; regimen has potential best-in-class profile."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-005424","json":"https://secwatch.observer/filing/0001193125-25-005424.json","markdown":"https://secwatch.observer/filing/0001193125-25-005424.md","text":"https://secwatch.observer/filing/0001193125-25-005424.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1593899/000119312525005424/0001193125-25-005424-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1593899/000119312525005424/d924755d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T02:03:50.105210+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}